|本期目录/Table of Contents|

[1]肖金凤,刘艳静,张欣欣,等.Graves病患者合并胸腺增生的影响因素分析[J].天津医科大学学报,2022,28(02):165-168.
　XIAO Jin-feng,LIU Yan-jing,ZHANG Xin-xin,et al.Analysis of influencing factors in patients with Graves' disease complicated with thymic hyperplasia[J].Journal of Tianjin Medical University,2022,28(02):165-168.
点击复制

Graves病患者合并胸腺增生的影响因素分析(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
28卷
期数:
2022年02期
页码:
165-168
栏目:
临床医学
出版日期:
2022-03-20

文章信息/Info

Title:
Analysis of influencing factors in patients with Graves' disease complicated with thymic hyperplasia
文章编号:
1006-8147(2022)02-0165-04
作者:
肖金凤; 刘艳静; 张欣欣; 何庆
（天津医科大学总医院内分泌代谢科，天津 300052）
Author(s):
XIAO Jin-feng;  LIU Yan-jing;  ZHANG Xin-xin;  HE Qing
（Department of Endocrinology and Metabolism，General Hospital，Tianjin Medical University，Tianjin 300052， China）
关键词:
Graves病; TRAb; 胸腺增生
Keywords:
Graves' disease;  TRAb;  thymic hyperplasia
分类号:
R581.1
DOI:
-
文献标志码:
A
摘要:
目的：分析Graves病患者合并胸腺增生的相关影响因素。方法：收集2018年11月—2020年11月临床确诊的Graves病患者100例，依据胸部CT结果分为两组：合并胸腺增生51例，未合并胸腺增生49例。分析两组年龄、病程、白细胞、中性粒细胞、肝功能、游离甲状腺功能（甲功）、促甲状腺素受体抗体（TRAb）、甲状腺过氧化物酶抗体（TPOAb）、甲状腺球蛋白抗体（TGAb）等相关指标。结果：本研究中Graves病合并胸腺增生发生率为51%；Graves病合并胸腺增生组与未合并胸腺增生组相比，年龄较小，谷丙转氨酶（ALT）、FT3、FT4水平较高（t=-4.216，Z=-2.321、-2.837、2.633，均P＜0.05）；单因素Logistic回归分析结果提示，年龄、FT3、FT4均与Graves病合并胸腺增生相关（OR=0.942、1.046、1.040，95%CI：0.913～0.972、1.010～1.082、1.008～1.073，均P＜0.05）；多因素Logistic回归分析结果提示，年龄是评价Graves病合并胸腺增生的独立危险因素（OR=0.946，95%CI：0.917～0.977，P＜0.05）；年龄预测Graves病伴胸腺增生的受试者工作特征曲线（ROC曲线）下面积为0.734（95%CI：0.632～0.836），截断值为48.5岁，灵敏性72.5%，特异性75.5%（P＜0.01）。结论：Graves病合并胸腺增生与TRAb水平无相关性，但与年龄呈负相关。
Abstract:
Objective： To analyze the related influencing factors in patients with Graves' disease complicated with thymic hyperplasia. Methods: A total of 100 patients with Graves' disease who were clinically diagnosed from November 2018 to November 2020 were enrolled in this study and divided into two groups based on chest CT findings：51 cases with thymic hyperplasia；49 cases without thymic hyperplasia. The age，course of disease，white blood cells，neutrophils， liver function，free thyroid function，TRAb，TGAb，TPOAb and other related indicators of the two groups of patients were analyzed. Results: In the study，the incidence of Graves' disease with thymic hyperplasia was 51%. Compared with the group without thymic hyperplasia， the age was younger in the group with thymic hyperplasia， while the ALT，FT3 and FT4 levels were higher，the difference was statistically significant（t=-4.216，Z=0.020，-2.837，2.633，all P<0.05）. The univariate Logistic regression analysis showed that age of onset，FT3，FT4 were all related to Graves' disease with thymic hyperplasia（OR=0.942，1.046，1.040，95%CI：0.913-0.972，1.010-1.082，1.008-1.073，all P<0.05）. The multivariate Logistic regression analysis showed that the age of onset was an independent risk factor for the evaluation of Graves' disease with thymic hyperplasia（OR=0.946，95%CI：0.917-0.977，P＜0.05）. The area under the ROC curve of age prediction of Graves' disease with thymic hyperplasia was 0.734（95%CI：0.632-0.836）， the cut-off value was 48.5 years old， the sensitivity was 72.5%， the specificity was 75.5%（P<0.01）. Conclusion: There is no relationship between thymic hyperplasia in patients with Graves' disease and TRAb level， but the age of onset is negatively correlated with thymic hyperplasia.

参考文献/References:

[1] PUJOL-BORRELL R，GIM?魪NEZ-BARCONS M，MAR?魱N-S?魣NCHEZ A， et al. Genetics of Graves' disease: special focus on the role of TSHR gene[J]. Horm Metab Res，2015，47（10）：753-766.
[2] SONG Y S，WON J K，KIM M J，et al. Graves' patient with thymic expression of thyrotropin receptors and dynamic changes in thymic hyperplasia proportional to Graves' disease activity[J]. Yonsei Med J，2016，57（3）：795-798.
[3] 中华医学会内分泌学分会《中国甲状腺疾病诊治指南》编写组.中国甲状腺疾病诊治指南——甲状腺功能亢进症[J]. 中华内科杂志，2007，46（10）： 876-882.
[4] GUNN A，MICHIE W，IRVINE W J. The thymus in thyroid disease[J]. Lancet，1964，2（7363）：776-778.
[5] JINGUJI M，NAKAJO M，NAKAJO M，et al. Thymic involution after radioiodine therapy for graves disease：relationships with serum thyroid hormones and TRAb[J]. J Endocr Soc，2017，1（7）：852-860.
[6] SUH H，ROSEN J E，DOHERTY G M，et al. Graves' disease and thymic hyperplasia[J]. Surgery，2013，154（6）：1473-1477.
[7] HAIDER U，RICHARDS P，GIANOUKAKIS A G. Thymic hyperplasia associated with Graves' disease： pathophysiology and proposed management algorithm[J]. Thyroid，2017，27（8）：994-1000.
[8] VAN HERLE A J，CHOPRA I J. Thymic hyperplasia in Graves' disease[J]. J Clin Endocrinol Metab，1971，32（2）：140-146.
[9] MURAKAMI M，HOSOI Y，NEGISHI T，et al. Thymic hyperplasia in patients with Graves' disease. Identification of thyrotropin receptors in human thymus[J]. J Clin Invest，1996，98（10）：2228-2234.
[10] GIM?魪NEZ-BARCONS M，COLOBRAN R，G?魷MEZ-PAU A，et al. Graves' disease TSHR-stimulating antibodies（TSAbs） induce the activation of immature thymocytes： a clue to the riddle of TSAbs generation[J]. J Immunol，2015，194（9）：4199-4206.
[11] VILLA-VERDE D M，DEFRESNE M P，VANNIER-DOS-SANTOS M A，et al. Identification of nuclear triiodothyronine receptors in the thymic epithelium[J]. Endocrinology，1992，131（3）：1313-1320.
[12] 张颖辉，王冰，万娅敏，等. Graves病与低钾性周期性麻痹和胸腺增生的关系[J]. 中国综合临床，2014，30（2）：174-176.
[13] DALLA COSTA M，MANGANO F A，BETTERLE C. Thymic hyperplasia in patients with Graves' disease[J]. J Endocrinol Invest，2014，37（12）：1175-1179.
[14] KAMATH C，WITCZAK J，ADLAN M A，et al. Managing thymic enlargement in Graves' disease[J]. Endocrinol Diabetes Metab Case Rep，2019，2019 ：18-0119.

相似文献/References:

备注/Memo

备注/Memo:
作者简介 胡天一（1972-），女，副主任医师，硕士，研究方向：儿童过敏性疾病以及呼吸系统疾病等；通信作者：陶枫，E-mail：tf9912@aliyun.com。
更新日期/Last Update: 2022-03-20